[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:somatostatin-receptor":3},{"name":4,"total":5,"recruiting":6,"trials":7},"Somatostatin Receptor",23,22,[8,16,23,30,36,42,49,55,61,67,73,80,86,92,98,104,110,116,122,128,134,140,146],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07150806","RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma",[12],"Phase 1\u002FPhase 2","RECRUITING","2026-08-26T02:17:22.949982Z","2026-05-29T15:36:40.180205Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT05477576","Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy",[20],"Phase 3","2026-08-26T02:16:20.336282Z","2026-05-05T02:43:29.713577Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":28,"content_modified":29},"NCT05583708","Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer",[27],"Phase 2","2026-08-26T02:15:03.757872Z","2026-05-05T02:43:29.698134Z",{"nct_id":31,"title":32,"phases":33,"status":13,"updated_at":34,"content_modified":35},"NCT04665739","Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors",[27],"2026-08-26T02:19:06.150683Z","2026-05-05T02:43:29.672724Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":40,"content_modified":41},"NCT04086485","Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)",[12],"2026-08-26T02:18:09.641312Z","2026-05-05T02:43:29.651483Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":47,"content_modified":48},"NCT05687123","Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors",[46],"Phase 1","2026-08-26T02:18:41.390601Z","2026-05-05T02:43:29.295160Z",{"nct_id":50,"title":51,"phases":52,"status":13,"updated_at":53,"content_modified":54},"NCT04082520","Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy",[27],"2026-08-26T02:15:02.712396Z","2026-05-05T02:43:29.226087Z",{"nct_id":56,"title":57,"phases":58,"status":13,"updated_at":59,"content_modified":60},"NCT07150546","Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors.",[46],"2026-08-26T02:17:36.611194Z","2026-05-05T02:43:29.200887Z",{"nct_id":62,"title":63,"phases":64,"status":13,"updated_at":65,"content_modified":66},"NCT06663072","Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors",[46],"2026-08-26T02:19:07.104270Z","2026-05-05T02:43:28.804469Z",{"nct_id":68,"title":69,"phases":70,"status":13,"updated_at":71,"content_modified":72},"NCT04609592","Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery",[46],"2026-08-03T01:59:18.089574Z","2026-05-05T02:43:28.703397Z",{"nct_id":74,"title":75,"phases":76,"status":13,"updated_at":78,"content_modified":79},"NCT06016855","Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors",[77],"Phase 4","2026-08-26T02:16:42.787115Z","2026-05-05T02:43:27.860078Z",{"nct_id":81,"title":82,"phases":83,"status":13,"updated_at":84,"content_modified":85},"NCT05773274","Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial",[27],"2026-08-26T02:17:20.511551Z","2026-05-05T02:43:27.798127Z",{"nct_id":87,"title":88,"phases":89,"status":13,"updated_at":90,"content_modified":91},"NCT03206060","Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma\u002F Paraganglioma",[27],"2026-08-26T02:17:45.190188Z","2026-05-05T02:43:27.070855Z",{"nct_id":93,"title":94,"phases":95,"status":13,"updated_at":96,"content_modified":97},"NCT06784752","Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET",[20],"2026-08-26T02:15:14.574786Z","2026-05-05T02:35:31.867759Z",{"nct_id":99,"title":100,"phases":101,"status":13,"updated_at":102,"content_modified":103},"NCT06427798","Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma\u002FParaganglioma Previously Treated With Systemic Targeted Radioligand Therapy",[12],"2026-08-26T02:18:45.196599Z","2026-07-05T05:32:16.752853Z",{"nct_id":105,"title":106,"phases":107,"status":13,"updated_at":108,"content_modified":109},"NCT05691465","Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells",[27],"2026-08-26T02:15:21.365312Z","2026-05-05T02:43:28.481085Z",{"nct_id":111,"title":112,"phases":113,"status":13,"updated_at":114,"content_modified":115},"NCT07165132","Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.",[46],"2026-08-26T02:17:27.435233Z","2026-05-05T02:43:27.257230Z",{"nct_id":117,"title":118,"phases":119,"status":13,"updated_at":120,"content_modified":121},"NCT05278208","Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors",[12],"2026-08-26T02:18:21.216897Z","2026-07-24T01:27:14.928126Z",{"nct_id":123,"title":124,"phases":125,"status":13,"updated_at":126,"content_modified":127},"NCT05636618","Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors",[12],"2026-08-26T02:17:03.534765Z","2026-07-05T05:32:16.808808Z",{"nct_id":129,"title":130,"phases":131,"status":13,"updated_at":132,"content_modified":133},"NCT06479811","[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma\u002FParagangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers",[46],"2026-08-26T02:17:34.833510Z","2026-05-05T02:43:28.023362Z",{"nct_id":135,"title":136,"phases":137,"status":13,"updated_at":138,"content_modified":139},"NCT06441331","Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors",[46],"2026-08-26T02:18:55.570428Z","2026-05-05T02:43:26.707134Z",{"nct_id":141,"title":142,"phases":143,"status":13,"updated_at":144,"content_modified":145},"NCT04090034","Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors",[],"2026-08-26T02:17:30.961790Z","2026-05-13T02:55:06.233960Z",{"nct_id":147,"title":148,"phases":149,"status":150,"updated_at":151,"content_modified":152},"NCT05160480","A Pilot Study of Total-body PET Using FDA-approved Radiotracers Beyond 18F-FDG",[],"ENROLLING_BY_INVITATION","2026-08-26T02:18:24.494016Z","2026-06-16T05:54:08.025989Z"]